JCA Meets AMNOG: German Benefit Assessments for Tarlatamab and Lurbinectedin Published
The German Federal Joint Committee (G-BA) has recently published its benefit assessments for tarlatamab and lurbinectedin, the second and third […]
Insights
When Better Models Meet Missing Overlap
What the Itvisma JCA says about designing evidence for questions someone else will define. The new Joint Clinical Assessment
AMNOG 2.0: A Second Assessment Does Not Yet Make a Learning System
Germany may be about to make AMNOG more adaptive. But the important question is not whether there will be a
NICE Updates its Approach with a New Relevant EQ-5D-5L Dataset: What Does the Change Mean for Patient Access and how Should Companies Prepare?
On 27 August 2026, the National Institute for Health and Care Excellence (NICE) confirmed the adoption of the EuroQoL 5-Dimension 5-Level
Beyond the Cancer Vaccine: When the Asset Is No Longer a Sufficient Unit of Value
Moderna’s melanoma result highlights a widening gap between how oncology creates clinical value and how medicines are owned, evidenced and
Abstract: Why Two Brand for One Molecule? Strategic Implications of Dual-Brand Approaches for Orphan Designations, Revenue Thresholds and Pricing in Germany
Authors: Katharina Wolff-Kuhne, PhD; Malte Glüsen, MSc; Dr. Lydia Frick, MSc, PhD; Dr. Matthias P. Schönermark, PhD, MD. Kintiga, Hannover,
Abstract: Inclusion of Caregiver Quality-of-Life in Economic Evaluations: Global HTA Perspectives and Impact
Authors: Marieke Schurer, MSc; Melanie van Riemsdijk, PharmD, PhD. Kintiga, Ghent, Belgium. Abstract OBJECTIVES In health technology assessments (HTA), inclusion of
Abstract: Challenge of ATMP Reimbursement and Patient Access in a Changing UK Landscape
Authors: Ben Barron-Millar, PhD; Malcolm Boyd, MSc. Kintiga, Cambridge, United Kingdom. Abstract OBJECTIVES Advances therapy medicinal products (ATMPs) present significant challenges
Abstract: AI-Assisted Data Extraction for Systematic Literature Reviews in HTA: Accuracy and Efficiency within a NICE-Aligned Workflow
Authors: Praptee Ghimire, MSc; Ben Lanning, PhD; Tejas Pethkar, BSc; Anna Macbeth, BSc; Jessica Radford, BSc; Priscila Mazzola, PhD. Kintiga,
From JCA to AMNOG: What Survives Downstream?
When the first Joint Clinical Assessment for tovorafenib was published, I described it as an “empty grid”. Eight PICOs had
